KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Change in Accured Expenses (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 13 years of Change in Accured Expenses data on record, last reported at $59.2 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 513.18% year-over-year to $59.2 million; the TTM value through Dec 2025 reached $46.6 million, up 208.44%, while the annual FY2025 figure was $46.6 million, 208.44% up from the prior year.
  • Change in Accured Expenses reached $59.2 million in Q4 2025 per IONS's latest filing, up from $10.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $59.2 million in Q4 2025 and bottomed at -$46.2 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $2.1 million, with a median of $3.1 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: plummeted 469.63% in 2021, then surged 748.92% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $6.5 million in 2021, then surged by 748.92% to $55.1 million in 2022, then crashed by 38.39% to $33.9 million in 2023, then crashed by 142.22% to -$14.3 million in 2024, then soared by 513.18% to $59.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $59.2 million in Q4 2025, $10.5 million in Q3 2025, and -$23.4 million in Q2 2025.